key: cord-0767708-11xjl53c
authors: Tan, C. S.; Collier, A.-r.; Liu, J.; Yu, J.; Wan, H.; McMahan, K.; He, X.; Jacob-Dolan, C.; Chandrashekar, A.; Sellers, D.; Stephenson, K.; Vidal, S.; Jaegle, K.; Curran, J.; Rowe, M.; Hemod, R.; Bermudez Rivera, L.; Anioke, T.; Barrett, J.; Chung, B.; Gardner, S.; Gebre, M.; Lifton, M.; Powers, O.; VanWyk, H.; Wu, C.; Barouch, D.
title: Ad26.COV2.S or BNT162b2 Boosting of BNT162b2 Vaccinated Individuals
date: 2021-12-05
journal: nan
DOI: 10.1101/2021.12.02.21267198
sha: a0b56b1de63da0568261293e858076efeb83e324
doc_id: 767708
cord_uid: 11xjl53c

Previous studies have reported that a third dose of the BNT162b2 (Pfizer) COVID-19 vaccine increased antibody titers and protective efficacy. Here we compare humoral and cellular immune responses in 65 individuals who were vaccinated with the BNT162b2 vaccine and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24).

Previous studies have reported that a third dose of the BNT162b2 (Pfizer) COVID-19 vaccine increased antibody titers and protective efficacy 1,2 . Here we compare humoral and cellular immune responses in 65 individuals who were vaccinated with the BNT162b2 vaccine and were boosted after at least 6 months with either Ad26.COV2.S 3 (Johnson & Johnson; N=41) or BNT162b2 4 (Pfizer; N=24) ( Table S1) .

Pseudovirus neutralizing antibody responses were detectable but low at six months following BNT162b2 vaccination, consistent with previous reports showing that serum antibody titers decline sharply following BNT162b2 vaccination 1, 5 . Ad26.COV2.S boosting increased median neutralizing antibody titers to the WA1/2020, delta, and beta variants to 1,462, 1,009, and 899 at week 2 following the boost, respectively, and these titers further increased 2.46-, 2.18-, and 2.14-fold to 3,597, 2,198, and 1,924 at week 4 following the boost (Fig. 1A , Table   S2 ). BNT162b2 boosting increased median neutralizing antibody titers to the WA1/2020, delta, and beta variants to 7,554, 2,978, and 1,865 at week 2 following the boost, respectively, and these titers declined to 5,553, 1,968, and 1,576 at week 4 following the boost (Fig. 1A , Table   S2 ).

Ad26.COV2.S boosting increased median receptor binding domain (RBD)-specific antibody titers by ELISA to the WA1/2020, delta, and beta variants to 11,264, 10,817, and 5,375 at week 2 following the boost, respectively, and these titers further increased to 16,311, 13,118, and 10,279 at week 4 following the boost (Fig. 1B) . BNT162b2 boosting increased median RBD-specific ELISA titers to the WA1/2020, delta, and beta variants to 30,730, 26,398, and 14,725 at week 2 following the boost, respectively, and these titers declined to 14,747, 13,037, and 7,230 at week 4 following the boost (Fig. 1B) . Similar trends were observed with an electrochemiluminescence binding antibody assay (ECLA) (Fig. S1) . These data show that . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint BNT162b2 boosting led to peak antibody titers at week 2, whereas Ad26.COV2.S led to peak antibody titers at week 4 or later. Binding and neutralizing antibody titers were comparable at week 4 following Ad26.COV2.S and BNT162b2 boosts.

Median S-specific IFN-γ CD8+ T cell responses to the WA1/2020, delta, and beta variants were boosted by Ad26.COV2.S to 0.078%, 0.072%, and 0.083%, respectively, and by BNT162b2 to 0.026%, 0.031%, and 0.018%, respectively (Fig. 1C) . Median S-specific IFN-γ CD4+ T cells to the WA1/2020, delta, and beta variants were boosted by Ad26.COV2.S to 0.095%, 0.101%, and 0.099%, respectively, and by BNT162b2 to 0.052%, 0.043%, and 0.043%, respectively (Fig. 1D) .

Median RBD-specific memory B cell responses were boosted by Ad26.COV2.S to 0.391% and by BNT162b2 to 0.388% (Fig. S2) . RBD-specific B cells exhibited primarily an activated memory phenotype at week 2 following both Ad26.COV2.S and BNT162b2 boosting (Fig. S3) .

These data demonstrate that both heterologous Ad26.COV2.S and homologous BNT162b2 increased antibody responses in individuals who were vaccinated at least 6 months previously with BNT162b2. Ad26.COV2.S and BNT162b2 led to similar antibody titers by week 4 following the boost immunization but exhibited different immune kinetics 5 .

Ad26.COV2.S led to greater increases in CD8+ T cell responses than BNT162b2. However, the durability of these immune responses remain to be determined. These data suggest different immune phenotypes following heterologous ("mix-and-match") compared with homologous boost strategies for COVID-19.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. 

The sponsor did not have any role in design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

DHB is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The authors report no other conflict of interest.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint

The authors thank the study participants, the Center for Virology and Vaccine Research, and the Department of Obstetrics and Gynecology for enrollment, collection, and processing samples for the BIDMC COVID-19 Biorepository. We thank MesoScale Discovery for providing the kits for the ECLA multiplexing kits used in this study.

A specimen biorepository at Beth Israel Deaconess Medical Center (BIDMC) obtained samples from individuals who received the BNT162b2 vaccine. The BIDMC institutional review board approved this study (2020P000361). Participants either continued follow-up in the biorepository and were boosted with 30 ug BNT162b2 clinically or were enrolled in the COV2008 study (NCT04999111) and were boosted with 5, 2.5, or 1x10 10 vp Ad26.COV2.S. An additional 16 participants who were not enrolled in the BIDMC biorepository were also enrolled in the COV2008 study. The Advarra institutional review board approved the COV2008 study (SSU00161543). All participants provided informed consent. Individuals were excluded if they had a history of SARS-CoV-2 infection, received other COVID-19 vaccines, or received immunosuppressive medications.

Pseudovirus neutralizing antibody assay . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint

The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were used to measure pseudovirus neutralizing antibodies as described previously. 6,7 In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co- SARS-CoV-2 neutralization titers were defined as the sample dilution at which a 50% reduction (NT50) in relative light units was observed relative to the average of the virus control wells.

SARS-CoV-2 spike receptor-binding domain (RBD)-specific binding antibodies in serum were assessed by ELISA as described previously. 6,7 96-well plates were coated with 2 μg/mL of SARS-CoV-2 WA1/2020, B.1.617.2 (delta), and B.1.351 (beta) RBD protein in 1× Dulbecco phosphate-buffered saline (DPBS) and incubated at 4 °C overnight. After incubation, plates were . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. solution for at least 30 minutes at room temperature shaking at 700 rpm with a digital microplate shaker. During blocking the serum was diluted to 1:5,000 in Diluent 100. The calibrator curve was prepared by diluting the calibrator mixture from MSD 1:9 in Diluent 100 and then preparing a 7-step 4-fold dilution series plus a blank containing only Diluent 100. The plates were then . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint washed 3 times with 150 μL of Wash Buffer (0.5% Tween in 1x PBS), blotted dry, and 50 μL of the diluted samples and calibration curve were added in duplicate to the plates and set to shake at 700 rpm at room temperature for at least 2 h. The plates were again washed 3 times and 50 μL of SULFO-Tagged anti-Human IgG detection antibody diluted to 1x in Diluent 100 was added to each well and incubated shaking at 700 rpm at room temperature for at least 1 h. Plates were then washed 3 times and 150 μL of MSD GOLD Read Buffer B was added to each well and the plates were read immediately after on a MESO QuickPlex SQ 120 machine. MSD titers for each sample was reported as Relative Light Units (RLU) which were calculated using the calibrator.

CD4+ and CD8+ T cell responses were quantitated by peptide-stimulated intracellular cytokine staining (ICS) assays, as previously described. 6 10 6 peripheral blood mononuclear cells well were re-suspended in 100 µL of R10 media supplemented with CD49d monoclonal antibody (1 µg/mL) and CD28 monoclonal antibody (1 µg/mL). Each sample was assessed with mock (100 µL of R10 plus 0.5% DMSO; background control), peptides (2 µg/mL), and/or 10 pg/mL phorbol myristate acetate (PMA) and 1 µg/mL ionomycin (Sigma-Aldrich) (100µL; positive control) and incubated at 37°C for 1 h. After incubation, 0.25 µL of GolgiStop and 0.25 µL of GolgiPlug in 50 µL of R10 was added to each well and incubated at 37°C for 8 h and then held at min. After staining, cells were washed twice with 2% FBS/DPBS buffer, followed by incubation with BV650 streptavidin (BD Pharmingen) for 10 min, then washed twice with 2% FBS/DPBS buffer. After staining, cells were washed and fixed by 2% paraformaldehyde. All data were acquired on a BD FACSymphony flow cytometer. Subsequent analyses were performed using . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint by Aqua dye and CD45 was used as a positive inclusion gate for all leukocytes. Within classswitched B cell population gated as CD19+ IgM-IgD-CD3-CD14-CD16-, SARS-CoV-2 RBDspecific B cells were identified as double positive for SARS-CoV-2 (WA1/2020) RBD proteins labeled with different fluorescent probes. The SARS-CoV-2-specific B cells were further distinguished according to CD21/CD27 phenotype distribution as previously described 9 .

Descriptive statistics were calculated using GraphPad Prism 8.4.3, (GraphPad Software, San Diego, California). Data are presented as median with interquartile range (IQR).

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint Data displayed as median (range or interquartile range= IQR) and n (%) *This participant self-identified their race as Hispanic BMI= body mass index Pregnant and lactating designations reflect status at the time of booster vaccine . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21267198 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. 

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Safety and Efficacy of Single-Dose